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ond, we cannot say unequivocally that the somatic cell
nucleus is reprogrammed as it coexists with the original
chromosomes from the ESC in the hybrid cell. To be
sure, the ESC chromosomes need to be eliminated
from the hybrid cell to see if the somatic cell nucleus
continues to display its new identity. Of course, being
able to remove the ESC chromosomes while retaining
the reprogrammed somatic nucleus would make this
procedure extremely valuable even if we do not under-
stand the mechanism. However, this is not possible at
present. Nevertheless, the likelihood that hESCs have
the potential to reprogram somatic cell nuclei is a big
step forward because it means that there is a large vol-
ume of biological material available for biochemical
characterization of the reprogramming factors present
in these cells. There is also the potential to develop cell-
based assays to hunt for these key reprogramming
factors.
But we also need to know the nature of the repro-
gramming factors themselves. A key requirement dur-
ing reprogramming is the efficient erasure of existing
epigenetic modifications associated with DNA and his-
tones. Are oocytes and ESCs equivalent in this re-
spect? Some studies suggest that certain forms of his-
tone modifications may be erased more efficiently in
the pluripotent epiblast compared to oocytes (Bao et
al., 2005; Santos et al., 2003). If ESCs inherit this prop-
erty from epiblast cells from which they are derived,
then this could make ESCs in some respects more effi-
cient at reprogramming somatic cells. The recent iden-
tification of a histone demethylase called LSD1 (Lee et
al., 2005; Metzger et al., 2005) could be an important
step forward if this or similar molecules have a role in
nuclear reprogramming. Indeed, we need to under-
stand the mechanism of nuclear reprogramming in
much greater detail, and the Cowan et al. study is cer-
tainly a step in this direction.
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Taking LSD1 to a New High
Histone modifications mediate changes in gene ex-
pression by altering the underlying chromatin struc-
ture or by serving as a binding platform to recruit
other proteins. One such modification, histone meth-
ylation, was thought to be irreversible until last year
when Shi and coworkers broke new ground with their
discovery of a lysine-specific histone demethylase
(LSD1). They showed that LSD1, a nuclear amine oxi-
dase homolog, is a bona fide histone H3 lysine 4 de-
methylase (Shi et al., 2004). Now, a new study from
Shi et al. (2005) published in a recent issue of Molecu-
lar Cell, together with two studies recently published
by Metzger et al. (2005) and Lee et al. (2005) in Nature,
reveal that LSD1’s specificity and activity is in fact
regulated by associated protein cofactors.
Development, cell proliferation, and cellular responses
to environmental signals are all orchestrated by coordi-
nated patterns of gene expression. DNA-encoded ge-
netic information is packaged into a chromatin polymer,
which must be opened to allow increased accessibility
for gene regulatory factors, or compacted to restrict ac-
cess of the transcriptional machinery to target genes.
In general, these “opened” and “closed” chromatin
states correspond to gene activation versus gene re-
pression, respectively.
What are the molecular switches that govern these
opposing states as cells attempt to activate some genes
while repressing others? A rich history of chromatin re-
search has provided longstanding clues as to what form
these switches might take, and the last decade has trans-
formed those early clues into hard evidence. Histone
modifications, such as acetylation, phosphorylation, and
methylation, are the switches that alter chromatin struc-
ture or form a binding platform for downstream “effec-
tor” proteins to allow transcriptional activation or re-
pression. Histone acetylation is the best characterized
histone modification. A steady-state balance between
histone acetylation and deacetylation and hence the
transcriptional competency of target genes depends on
the interplay of opposing enzymatic activities: forward
reactions catalyzed by histone acetyltransferases and
reverse reactions catalyzed by histone deacetylases.
Exciting recent findings are rapidly extending these les-
sons to another form of chromatin modification, his-
tone methylation.
About five years ago, the first methyl lysine-adding
enzymatic activity was identified using histone H3 as
a substrate (Rea et al., 2000). However, methylation of
histones was thought to be different from acetylation
or phosphorylation in that it was not reversible due to
the high thermodynamic stability of the N-CH bond.3
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whether promoting activation of gene expression, for
example, through methylation of lysine 4 (K4) on histone
H3 (see Figure 1A), or repressing gene expression
through methylation of lysine 9 (K9) on histone H3 (Fig-
ure 1B). Not only does the particular “site” of methyla-
tion matter, but also the methylation “state” because
methylated lysine can come in multiple flavors (mono-,
di-, and trimethyl). Thus, as is often the case in biology,
the devil is in the details, and with histone methylation,
every detail is likely to be critical for the biological
outcome.
Although most research has focused on the role of
histone modifications, such as acetylation and methyl-
ation in gene regulation and other epigenetic phenom-
ena, there is increasing recognition that histone modifi-
cations are an important component of human disease,
notably cancer. A recent study reported the potential
application of global changes in specific histone acety-
lation and methylation marks as predictors of clinical
outcome for certain low-grade prostate cancers (Selig-
son et al., 2005). The importance of lysine methylation
in human disease is also underscored by the wide
range of different methyltransferases that correlate with
carcinogenesis when mutated (Schneider et al., 2002).
Last year, Shi and coworkers turned the world of his-
tone methylation upside down. They presented evi-
dence that LSD1, a nuclear amine oxidase homolog, is
a bona fide histone lysine demethylase (Shi et al.,
2004). LSD1 is highly conserved between organisms
ranging from the fission yeast Saccharomyces pombe
to humans. It contains a carboxyl-terminal amine oxi-
dase domain as well as a centrally located SWIRM
domain, a protein-protein interaction motif found in
multiple chromatin-associated proteins. The oxidation
reaction catalyzed by LSD1 is dependent on the cofac-
tor flavin adenine dinucleotide (FAD) and generates an
unmodified lysine and a formaldehyde byproduct at the
end of its catalytic cycle (Shi et al., 2004). Remarkably,
recombinant LSD1 is highly specific for mono- and di-
methylated H3 K4 (see Figure 2, upper panel), whereas
other known major methylation sites in the tails of H3
and H4 histones are not its substrates. Demethylation
of trimethylated lysine, however, is prevented by the
absence of a protonated nitrogen required for oxida-
tion. Consistent with its role in removal of an “active”
methylation mark thereby promoting repression of gene
expression, LSD1 is found in corepressor complexes
(Shi et al., 2004). As a component of these complexes,
LSD1 associates with other histone-modifying enzymes
such as histone deacetylases and methyltransferases.
In concert with transcriptional repression, loss of LSD1
function leads to derepression of genes regulated by
CoREST, a protein involved in gene silencing and a
member of the LSD1 complex (Shi et al., 2004).
Although the discovery of the first lysine demethylase
represents a major breakthrough in chromatin biology,
it also raises many questions. For example, how can
the regulatory complexity of histone demethylation be
accomplished with only ten LSD1-related proteins
(Kubicek and Jenuwein, 2004)? For comparison, the
corresponding regulation of histone methylation re-
quires over 70 proteins that contain the specific motif
(SET domain) responsible for methylation. One possi-Figure 1. The Methylation of Histone Lysines Is Reversible and Reg-
ulates Gene Expression
(A) Methylation of H3 K4 is often associated with active genes, and
conversely, its demethylation accompanies gene repression.
(B) In contrast, methylation of H3 K9 is often associated with si-
lenced genes, hence removal of H3 K9 methyl marks coincides with
gene activation.bility is that the specificity and activity of LSD1 can be
modulated by association with specific cofactors.
Three recent papers demonstrate that this scenario is
indeed likely (Lee et al., 2005; Metzger et al., 2005; Shi
et al., 2005) and also reinforce the general view that
histone methylation is a reversible modification with
far-reaching implications for human disease.
Metzger et al. (2005) now report in Nature that they
have isolated LSD1 in a search for new proteins associ-
ated with the androgen receptor. Androgen receptor
belongs to a nuclear-receptor family of proteins that,
upon binding of ligand, regulates expression of genes
containing androgen-response DNA elements. In-
creased expression of androgen receptor and activa-
tion of its target genes appears to be an important
mechanism for the conversion of metastatic prostate
cancer into a treatment-resistant form (Chen et al.,
2004). Metzger et al. (2005) provide evidence that de-
methylation of lysine residues could also have impor-
tant implications for this process. LSD1 directly associ-
ates with the androgen receptor and, surprisingly, acts
as a coactivator for transcriptional activation by the an-
drogen receptor. Binding of ligand to the androgen re-
ceptor coincides with the loss of the repressive H3 K9
methylation from the androgen-response DNA element
but, interestingly, has no effect on H3 K4 methylation
(see Figure 2, bottom panel). Using pargyline as an in-
hibitor of the amine oxidase activity of LSD1 and gene
knockdown through RNA interference, the authors de-
monstrate that LSD1 is responsible for demethylation
of the mono- and dimethyl forms of H3 K9. Further-
more, LSD1 is required for transcriptional activation
mediated by the androgen receptor, but not that medi-
ated by the estrogen receptor or retinoic acid receptor.
LSD1 affinity-purified in the presence, but not in the
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656Figure 2. Regulation of LSD1 Specificity by Association with Protein Cofactors
(Upper panel) Recombinant LSD1 specifically demethylates H3 K4 of core histones (A), but not H3 K9 (B) (Shi et al., 2004). (C) LSD1 demeth-
ylates H3 K9 when affinity purified in the presence of the androgen receptor (AR; Metzger et al., 2005).
(Middle panel) (A) Recombinant LSD1 alone does not bind to or act upon nucleosomal substrates. (B) Association of LSD1 with CoREST
endows LSD1 with the ability to demethylate H3 K4 on nucleosomal substrates (Lee et al., 2005; Shi et al., 2005). (C) BHC80 inhibits the
demethylation of nucleosomes mediated by the LSD1-CoREST complex (Shi et al., 2005).
(Lower panel) (A) LSD1, as part of the CoREST corepressor complex, is recruited to genes containing the REST-responsive repressor element
1 (RE1) and participates in gene silencing through demethylation of H3 K4 (Shi et al., 2004). (B) Ligand-induced recruitment of androgen
receptor (AR) to the androgen receptor element (ARE) is accompanied by demethylation of H3 K9 by LSD1, leading to transcriptional activation
(Metzger et al., 2005). However, LSD1 is already tethered to the ARE through an unknown mechanism (indicated by factor X) prior to the
induction of gene expression by the androgen ligand.absence, of androgen receptor can demethylate H3 K9.
This suggests that the androgen receptor itself or alter-
natively one of its associated proteins is able to modu-
late the specificity of LSD1 (Figure 2, top panel). Thus,
this study shows a new, cofactor-regulated specificity
for histone demethylation and demonstrates that LSD1
can act as a transcriptional coactivator. It also shows
that monoamine oxidase inhibitors, such as pargyline,
can inhibit LSD1, which may prove useful in the studies
of histone demethylases and have important therapeu-
tic implications for prostate cancer.
Several important questions remain to be addressed.
For example, it remains unclear whether the purified
LSD-androgen receptor complex fails to use methyl-
ated H3 K4 as a substrate in vitro. Also, association of
LSD1 with androgen-response DNA elements is inde-
pendent of the presence of androgen receptor at the
promoter. How then is LSD1 tethered to androgen-
response DNA elements if it is not directly recruited by
the androgen receptor? In one possible scenario, LSD1
may be present at the promoter in a repressive complex
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mrior to induction of gene expression by a ligand (Figure
, bottom panel). Once the androgen receptor interacts
ith its ligand, this complex associates with LSD1,
hich may alter its specificity, thereby converting it
rom a repressor of gene expression into an activator.
owever, reduced lysine 4 methylation is not observed
hen LSD1 is bound in the absence of androgen recep-
or, indicating that bound LSD1 may be present in an
nzymatically inactive conformation. Further studies to
nvestigate the presence or absence of LSD1-associ-
ted repressor complexes at androgen receptor targets
ay shed light on these issues. Another interesting and
nexplained observation is that H3 K9 trimethylation
ppears to be altered upon activation of the androgen
eceptor by its ligand. This effect is independent of
SD1, consistent with the inability of FAD-dependent
mine oxidases to use trimethylated lysines as sub-
trates. What enzymatic activities are responsible for
oss of H3 K9 trimethylation upon activation of the an-
rogen receptor? Finally, it will be essential to deter-
ine the structural basis of the substrate recognition
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ceptor.
The studies by Lee et al. (2005) and Shi et al. (2005)
address the role of cofactor association in the regula-
tion of LSD1 activity in transcriptional repression
through demethylation of H3 at the K4 position. Al-
though insights into this regulation are certainly of great
interest, such regulatory mechanisms are not unprece-
dented in chromatin biology. In the early days of acety-
lation, recombinant catalytic enzymes were found to
behave quite differently from the multisubunit com-
plexes that contained them (Grant and Berger, 1999).
Moreover, the form of the substrate was critical, as core
histone substrates were affected differently from
nucleosomal substrates in a manner often dependent
on association with other proteins. Now, work by two
groups demonstrates that this mode of regulation can
be extended to histone demethylases, as activity of
LSD1 toward nucleosomes is regulated by a cofactor
(Lee et al., 2005, Shi et al., 2005). Both groups focused
their attention on CoREST, a member of an LSD1-con-
taining complex, whose components are well defined
(Hakimi et al., 2002). CoREST is recruited by the si-
lencer REST to repress transcription of neuronal genes
(Hakimi et al., 2002; see Figure 2, bottom panel).
Through in vitro reconstitution of the complex, Lee et al.
(2005) functionally dissect the role of the polypeptides
present in the CoREST complex. In a complementary
study, Shi et al. (2005) show that two members of the
LSD1 complex, CoREST and BHC80, have opposing ef-
fects on LSD1 activity. Both groups demonstrate that
CoREST endows LSD1 with the ability to associate with
and demethylate nucleosomal substrates (see Figure 2,
middle panel). Lee et al. (2005) conclude that the pres-
ence of either one of the two SANT domains of CoREST,
a protein motif present in many chromatin-associated
proteins, is necessary for its association with LSD1 and
for demethylation of nucleosomes. In contrast, Shi et
al. (2005) demonstrate that a region situated toward the
amino terminal of the second SANT domain of CoREST
binds to LSD1 and that, in conjunction with this binding
domain, the second SANT domain alone is sufficient for
the stimulation of LSD1 enzymatic activity. Whatever
the case, these results suggest a mechanism whereby
CoREST binds to LSD1 and tethers it to the nucleosome,
bringing the amine oxidase domain close to the H3 tail.
Both groups show that CoREST knockdown through
small interfering RNAs results in the increase of H3 K4
dimethylation at the REST-dependent promoter, under-
scoring the importance of CoREST as a cofactor for the
histone demethylase. Shi et al. (2005), however, delve
deeper into a possible regulatory mechanism by mak-
ing the interesting observation that CoREST is required
not only for the activity, but also for the stability of
LSD1, in a proteasome-pathway-dependent manner.
This group also showed that another component of the
CoREST complex, BHC80, inhibits demethylation of
nucleosomes mediated by the LSD1-CoREST complex.
This adds to the potential complexity of the regulation
of LSD1 activity within the CoREST complex (Shi et al.,
2005; see Figure 2, middle panel).
Perhaps the most important discrepancy between
the results described by Lee et al. (2005) compared
with those described by Shi et al. (2005) is related tothe involvement of histone deacetylation in the activity
of LSD1. Lee et al. (2005) argue that the demethylase
activity of the CoREST complex is unaffected by inhibi-
tion of the histone deacetylases present in the com-
plex, suggesting that the demethylation reaction does
not require prior deacetylation and that LSD1 can act
upon acetylated substrates. In contrast, Shi et al. (2005)
show that hypoacetylated nucleosomes are more sus-
ceptible substrates for demethylation than their hyper-
acteylated counterparts. The authors also note that the
SANT domain of another corepressor, SMRT, binds
preferentially to hypoacetylated histone tails (Yu et al.,
2003). Thus, the results described by Shi et al. (2005)
suggest a model whereby deacetylation of nucleo-
somes by histone deacetylases sets the stage for de-
methylation, possibly by allowing for tighter binding of
the CoREST SANT domain to the nucleosomes, which
in turn results in increased recruitment of LSD1 to nucleo-
somal substrates. Although discrepancies between the
two papers need to be resolved, given the fact that
LSD1 is accompanied by histone deacetylases in vari-
ous protein complexes, and mindful of lessons learned
from other histone modifications, we think that cross-
talk between the deacetylation and demethylation
pathways is very plausible.
Together, these three studies add to the continually
evolving world of histone modifications in general and
lysine demethylation in particular. Clearly, there is
much gold left to be mined from the study of histone
methylation and the enzyme systems responsible for
the balance between methylation and demethylation.
Although new evidence suggests that histone methyla-
tion marks may not be as stable as was first thought,
we conclude that histone demethylation is here to stay.
Joanna Wysocka, Thomas A. Milne,
and C. David Allis
Laboratory of Chromatin Biology
The Rockefeller University
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